No

Androgen

Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who, without definite pathophysiologic reasons, fail to gain or to maintain normal weight

C-III

X

Nephrosis, carcinoma of breast or prostate, pregnancy, hypersensitivity to oxandrolone or any component

May stunt bone growth in children; anabolic steroids may cause peliosis hepatis, liver cell tumors, and blood lipid changes with increased risk of arteriosclerosis; monitor diabetic patients carefully; use with caution in elderly patients, they may be at greater risk for prostatic hypertrophy; use with caution in patients with cardiac, renal, or hepatic disease or epilepsy

Male:

Postpubertal:

>10%:

Dermatologic: Acne

Endocrine & metabolic: Gynecomastia

Genitourinary: Bladder irritability, priapism

1% to 10%:

Central nervous system: Insomnia, chills

Endocrine & metabolic: Decreased libido, hepatic dysfunction

Gastrointestinal: Nausea, diarrhea

Genitourinary: Prostatic hypertrophy (elderly)

Hematologic: Iron deficiency anemia, suppression of clotting factors

<1%: Hepatic necrosis, hepatocellular carcinoma

Prepubertal:

>10%:

Dermatologic: Acne

Endocrine & metabolic: Virilism

1% to 10%:

Central nervous system: Chills, insomnia,

Dermatologic: Hyperpigmentation

Gastrointestinal: Diarrhea, nausea

Hematologic: Iron deficiency anemia, suppression of clotting factors

<1%: Hepatic necrosis, hepatocellular carcinoma

Female:

>10%: Endocrine & metabolic: Virilism

1% to 10%:

Central nervous system: Chills, insomnia

Endocrine & metabolic: Hypercalcemia

Gastrointestinal: Nausea, diarrhea

Hematologic: Iron deficiency anemia, suppression of clotting factors

Hepatic: Hepatic dysfunction

<1%: Hepatic necrosis, hepatocellular carcinoma

Increased toxicity: ACTH, adrenal steroids may increase risk of edema and acne; stanozolol enhances the hypoprothrombinemic effects of oral anticoagulants; enhances the hypoglycemic effects of insulin and sulfonylureas (oral hypoglycemics)

Synthetic testosterone derivative with similar androgenic and anabolic actions

Onset: 1 month

Absorption: Oral absorption is high

Distribution: V_d: 0.578 L/kg

Protein binding, plasma: 94% to 97%

Metabolism: In an analogous fashion to testosterone in the liver

Excretion: 60% renal; 3% feces

Children: Total daily dose: less than or equal to 0.1 mg/kg or less than or equal to 0.045 mg/lb

Adults: 2.5 mg 2-4 times/day; however, since the response of individuals to anabolic steroids varies, a daily dose of as little as 2.5 mg or as much as 20 mg may be required to achieve the desired response. A course of therapy of 2-4 weeks is usually adequate. This may be repeated intermittently as needed.

Dosing adjustment in renal impairment: Caution is recommended because of the propensity of oxandrolone to cause edema and water retention

Dosing adjustment in hepatic impairment: Caution is advised but there are not specific guidelines for dosage reduction

May cause insomnia

None reported

No information available to require special precautions

No effects or complications reported

High protein, high caloric diet is suggested, restrict salt intake; glucose tolerance may be altered in diabetics

Tablet: 2.5 mg